Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 1973-1979

  Hashimoto, K ^a   Tsuda, H ^a   Koizumi, F ^a   Shimizu, C ^a   Yonemori, K ^a   Ando, M ^a   Kodaira, M ^a   Yunokawa, M ^a   Fujiwara, Y ^a   Tamura, K ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

biomarkers; HER4:PI3K; MAPK; prognosis; triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERBB4 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTOR, ERBB-4; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925452361     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu247     Document Type: Article

References (21)

1. Sorlie, T., Tibshirani, R., Parker, J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 (2003), 8418–8423.
2. Cheang, M.C., Voduc, D., Bajdik, C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14 (2008), 1368–1376.
3. Carey, L.A., Dees, E.C., Sawyer, L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007), 2329–2334.
4. Kalinsky, K., Jacks, L.M., Heguy, A., et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15 (2009), 5049–5059.
5. Berns, K., Horlings, H.M., Hennessy, B.T., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12 (2007), 395–402.
6. Weigelt, B., Warne, P.H., Downward, J., PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30 (2011), 3222–3233.
7. Carpten, J.D., Faber, A.L., Horn, C., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007), 439–444.
8. Zhao, J.J., Liu, Z., Wang, L., et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102 (2005), 18443–18448.
9. Sebolt-Leopold, J.S., Herrera, R., Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4 (2004), 937–947.
10. Allred, D.C., Harvey, J.M., Berardo, M., Clark, G.M., Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11 (1998), 155–168.
11. Wolff, A.C., Hammond, M.E., Schwartz, J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007), 118–145.
12. Board, R.E., Thelwell, N.J., Ravetto, P.F., et al. Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 54 (2008), 757–760.
13. Witton, C.J., Reeves, J.R., Going, J.J., et al. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. J Pathol 200 (2003), 290–297.
14. Thor, A.D., Edgerton, S.M., Jones, F.E., Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol 175 (2009), 1802–1809.
15. Naresh, A., Long, W., Vidal, G.A., et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 66 (2006), 6412–6420.
16. Eralp, Y., Derin, D., Ozluk, Y., et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol 19 (2008), 669–674.
17. Ellis, M.J., Lin, L., Crowder, R., et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119 (2010), 379–390.
18. Ginestier, C., Hur, M.H., Charafe-Jauffret, E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1 (2007), 555–567.
19. Fu, P., Ibusuki, M., Yamamoto, Y., et al. Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression. Breast Cancer Res Treat 130 (2011), 307–317.
20. Derin, D., Eralp, Y., Ozluk, Y., et al. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Cancer Invest 26 (2008), 671–679.
21. Aleskandarany, M.A., Rakha, E.A., Ahmed, M.A., et al. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat 127 (2011), 407–416.